Clinical Malaria

The Clinical Malaria Group conducts blood-stage controlled human malaria infection (CHMI) studies in healthy volunteers to evaluate the safety and efficacy of candidate anti-malarials.

Associate Professor Bridget Barber

Group Leader

Research Focus

The controlled human malaria infection (CHMI) model has been used to evaluate >10 investigational medicinal products. Models have been established for an artemisinin-sensitive and an artemisinin-resistant P. falciparum strain and other Plasmodium species including P. vivax, P. malariae, and P. knowlesi. The model has also enabled the conduct of studies to evaluate transmission-blocking interventions and has enabled the conduct of exploratory studies to evaluate immunological and pathophysiological response to infection.

Gallery

Research Projects

Current Research Projects

Clinical trials to evaluate candidate anti-malarials.

Using the IBSM model to improve understanding of the pathogenesis of malaria.


Research Team

Adam Potter

Arya SheelaNair

Azrin Rahman

Fiona Amante


Funding

  • Clinical trials to evaluate candidate anti-malarials.
  • The Bill and Melinda Gates Foundation.

Publications

Transmission blocking activity of low-dose Tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum.

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum

Read more